Long-term follow-up of people treated with ARD103 CAR-T cell therapy
Follows people with leukemia or myelodysplastic syndrome after ARD103 CAR-T cell treatment, checking long-term safety.
Plain-language title generated from the registry record
Registry title: A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies
Key facts
- Where
- Charlotte, Houston, and Winston-Salem, United StatesSee the 3 sites
Where in United States
- Novant Health Cancer InstituteCharlotte, United StatesTaking people
- MD Anderson Cancer CenterHouston, United StatesTaking people
- Novant Health Cancer InstituteWinston-Salem, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- ARCE Therapeutics, Inc.
- Trial code
- NCT06906380
- Record updated
- 30 October 2026
- Original description
This study will evaluate the long-term safety of ARD103 cellular therapiesRead full original descriptionShow less
A Long-term Follow-up Study of Patients Enrolled in ARD103_ARCE-CL-P-001 Phase 1/2 Study and Treated With ARD103 CAR-T Cell Therapies
This study will evaluate the long-term safety of ARD103 cellular therapies
Inclusion: The participant has R/R AML or MDS and has previously received ARD103 CAR-T cell therapies in the parent study; The participant is able to understand and comply with protocol-required study procedures and has provided a written informed consent document.
Exclusion: There are no specific exclusion criteria for this study.